Menu Back to DIA-2015-51st-Annual-Meeting-Develop-Innovate-Advance


DIA 2015 51st Annual Meeting: Develop.  Innovate.  Advance.

The DIA 2015 51st Annual Meeting brings together a global community of life sciences professionals at all levels and across all disciplines all with a common goal to foster innovation that will lead to the development of safe and effective medical products and therapies to patients.

The DIA Annual Meeting provides the best opportunity to meet with people from around the world, share your views and knowledge, network, and build new relationships.

Who should attend?

The DIA Annual Meeting is designed for individuals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, and related medical products.

Learning objectives

  • Provide a global unbiased platform to raise the level of discussion to facilitate innovation that will change the future of health care
  • Provide comprehensive coverage of the full development and life cycle management of process for all health care products
  • Offer a holistic and integrated approach to the development life cycle management of regulated health care products

Program Committee

  • Christopher P. Austin, MD
    Christopher P. Austin, MD Director, National Center for Advancing Translational Sciences
    National Institutes of Health (NIH), United States
  • Michael  Rosenblatt, MD
    Michael Rosenblatt, MD Executive Vice President and Chief Medical Officer
    Merck & Co., Inc., United States
  • J. Lynn  Bass, PharmD, RPh
    J. Lynn Bass, PharmD, RPh Director, Medical Affairs
    Jazz Pharmaceuticals, United States
  • Daniel M. Bollag, PhD
    Daniel M. Bollag, PhD Senior Vice President, Regulatory Affairs and Quality
    Ariad Pharmaceuticals Inc., United States
  • Linda F. Bowen, MS, RAC
    Linda F. Bowen, MS, RAC Head, US Regulatory Policy and Intelligence
    Sanofi, United States
  • Jonca C. Bull, MD
    Jonca C. Bull, MD Assistant Commissioner for Minority Health, Office of the Commissioner
    FDA, United States
  • Bill  Byrom, PhD
    Bill Byrom, PhD Senior Director, Product Innovation
    ICON plc, United Kingdom
  • Joy A. Cavagnaro, PhD, RAC
    Joy A. Cavagnaro, PhD, RAC President
    Access BIO, United States
  • Karla  Childers, MS
    Karla Childers, MS Senior Director, Strategic Projects, Office of the Chief Medical Officer
    Johnson & Johnson, United States
  • Leah  Christl, PhD
    Leah Christl, PhD Associate Director for Therapeutic Biologics, TBBS, OND, CDER
    FDA, United States
  • Betsy  Fallen, RN
    Betsy Fallen, RN Global Head of Program and Business Development
    Safe-BioPharma Association, United States
  • Ron D. Fitzmartin, PhD, MBA
    Ron D. Fitzmartin, PhD, MBA Senior Advisor, Office of Strategic Programs, CDER
    FDA, United States
  • Michael  Folkendt, MS
    Michael Folkendt, MS Associate Director, Office of Programs and Regulatory Operations, OPQ, CDER
    FDA, United States
  • Elizabeth E. Garrard, PharmD
    Elizabeth E. Garrard, PharmD Executive Vice President, Global Safety Operations
    Clinipace Worldwide, United States
  • Jonathan  Haddad, MPH, MT
    Jonathan Haddad, MPH, MT Director, Clinical Statistics
    GlaxoSmithKline, United States
  • Martin  Harvey Allchurch, LLM
    Martin Harvey Allchurch, LLM Principal International Affairs Officer
    European Medicines Agency, European Union , United Kingdom
  • Jonathan Solomon Helfgott, MS
    Jonathan Solomon Helfgott, MS Coordinator for Regulatory Science Program
    Johns Hopkins University, United States
  • Deborah J. Henderson, MSN
    Deborah J. Henderson, MSN Executive Director, Global Regulatory Policy
    Merck & Co., Inc., United States
  • Rima  Izem, PhD
    Rima Izem, PhD Lead Mathematical Statistician, Office of Translational Science, CDER
    FDA, United States
  • Janet  Jenkins-Showalter
    Janet Jenkins-Showalter Head, US Regulatory Policy
    Genentech, A Member of the Roche Group, United States
  • John  Kamp, JD, PhD
    John Kamp, JD, PhD Executive Director
    Coalition For Healthcare Communication, United States
  • Ellen  Kelso
    Ellen Kelso Executive Director
    Chesapeake IRB, United States
  • Lisa Palladino Kim, MS
    Lisa Palladino Kim, MS Faculty
    Rutgers, The State University of New Jersey, United States
  • Lynn  King, MHA
    Lynn King, MHA Senior Director, Clinical Operations
    TKL Research, Inc., United States
  • Agnes V. Klein, DrPH, MD
    Agnes V. Klein, DrPH, MD Director, Evaluation of Radiopharmaceuticals and Biotherapeutic Products
    Health Canada, Canada
  • Stephen  Knowles, MD, MRCP
    Stephen Knowles, MD, MRCP Senior Director, Global Patient Safety, Medical and Benefit Risk Management
    Eli Lilly and Company, United States
  • Mark A. Kryah, PMP
    Mark A. Kryah, PMP Senior Advisor/COO, Pharmaceutical Project Management
    Eli Lilly and Company, United States
  • JeanMarie  Markham
    JeanMarie Markham Chief Executive Officer
    Clinlogix LLC, United States
  • Philomena  McArthur, JD
    Philomena McArthur, JD Senior Director, Regulatory Advertising and Promotion and Healthcare Compliance
    Johnson & Johnson International, United States
  • Ann  Meeker-O'Connell, MS
    Ann Meeker-O'Connell, MS Head, Risk Management and External Engagement, Bioresearch Quality & Compliance
    Johnson & Johnson, United States
  • Jon  Meyer, MBA, MSc
    Jon Meyer, MBA, MSc Co-Founder and Managing Member
    Life Science Strategy Group, LLC, United States
  • Mary Stober Murray, MBA
    Mary Stober Murray, MBA Associate Director, Diversity and Patient Engagement
    Bristol-Myers Squibb Company, United States
  • Bob  Muzerall
    Bob Muzerall Vice President, Sales and Sales Training
    AMPLEXOR Life Sciences, LLC, United States
  • Nancy Bradish Myers, JD
    Nancy Bradish Myers, JD President
    Catalyst Healthcare Consulting, Inc, United States
  • Jane E. Myles, MS
    Jane E. Myles, MS Head, Operational Intelligence and Innovation
    Genentech, A Member of the Roche Group, United States
  • Roger  Nosal, MA, MS
    Roger Nosal, MA, MS Vice President and Head, Global CMC
    Pfizer Inc , United States
  • Pradip  Paul, MD, MS
    Pradip Paul, MD, MS Consultant
    Strategic Pharmacovigilance and Risk Management, United States
  • Kirsten H. Paulson, MS, RAC
    Kirsten H. Paulson, MS, RAC Senior Director, Global CMC Medical Devices
    Pfizer Inc, United States
  • Julia  Petses, PharmD
    Julia Petses, PharmD Director, Medical Information Services, Diabetes
    Sanofi US, United States
  • Christine  Pierre, RN
    Christine Pierre, RN President
    Society for Clinical Research Sites, United States
  • James E. Polli, PhD
    James E. Polli, PhD Prof.; Ralph F. Shangraw/Noxell Endowed Chair, Ind. Pharmacy & Pharmaceutics
    University of Maryland School of Pharmacy, United States
  • Sarah  Pope Miksinski, PhD
    Sarah Pope Miksinski, PhD Acting Director, Office of New Drug Products, OPQ, CDER
    FDA, United States
  • Badri  Rengarajan, MD
    Badri Rengarajan, MD Medical Affairs Head, ASPIRE Unit
    Actelion, United States
  • Matthew D. Rotelli, PhD
    Matthew D. Rotelli, PhD Director, Global PK/PD and Pharmacometrics, Bio-Medicines
    Eli Lilly and Company, United States
  • Leslie M. Sam
    Leslie M. Sam Director, Global Quality Systems, Safety, Efficacy and Customer Information
    Eli Lilly and Company, United States
  • Abdul J. Sankoh, PhD, MA, MS
    Abdul J. Sankoh, PhD, MA, MS Vice President, Biostatistics and Statistical Programming
    FORUM Pharmaceuticals, United States
  • Suzanne  Sensabaugh, MBA, MS
    Suzanne Sensabaugh, MBA, MS President and Principal Consultant
    HartmannWillner LLC, United States
  • Ashley F. Slagle, PhD, MS
    Ashley F. Slagle, PhD, MS Scientific and Regulatory Consultant
    Aspen Consulting, LLC, United States
  • Nancy  Smerkanich
    Nancy Smerkanich Educational Liaison and Instructor, International Center for Regulatory Science
    University of Southern California, United States
  • Maureen  Smith
    Maureen Smith Patient Advocate / Secretary
    Canadian Organization For Rare Disorders (CORD), Canada
  • William B. Smith, MD
    William B. Smith, MD President
    VRG/New Orleans Center for Clinical Research, United States
  • Ling  Su, PhD
    Ling Su, PhD Strategic Advisor, Life Sciences
    Sidley Austin LLP, China
  • Sameer  Thapar, PharmD
    Sameer Thapar, PharmD Director, Global PV, Oracle; Assistant Professor, Drug Safety and PV
    Rutgers, The State University of New Jersey, United States
  • Toshiyoshi  Tominaga, PhD
    Toshiyoshi Tominaga, PhD Associate Executive Director (for International Programs)
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Linda Fossati Wood, MPH, RN
    Linda Fossati Wood, MPH, RN President
    MedWrite, Inc., United States
Load More

Contact us

DIA Americas
800 Enterprise Road, Suite 200
Horsham, PA 19044-3595, USA
Phone: +1 215 442 6100
Fax: +1 215 442 6199

Questions related to the DIA 2015 51st Annual Meeting Program? Contact:

Ways to register

Registration override should work.